SQ 29,548 is primarily used in research settings as a potent and selective thromboxane A2 receptor antagonist. It is widely utilized in studies to investigate the role of thromboxane A2 in various physiological and pathological processes, such as platelet aggregation, vasoconstriction, and inflammation. Researchers employ it to understand its potential therapeutic effects in conditions like cardiovascular diseases, asthma, and renal disorders. Additionally, SQ 29,548 is instrumental in exploring the mechanisms of thromboxane A2-mediated signaling pathways and their impact on cellular responses. Its application extends to in vitro and in vivo experiments aimed at developing targeted therapies for diseases associated with thromboxane A2 activity.